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Abstract 
 
The growth of pharmaceutical expenditure and its prediction is a major concern for 
policy makers and health care managers. This paper explores different predictive 
models to estimate future drug expenses, using demographic and morbidity individual 
information from an integrated healthcare delivery organization in Catalonia for years 
2002 and 2003. The morbidity information consists of codified health encounters 
grouped through the Clinical Risk Groups (CRGs). We estimate pharmaceutical costs 
using several model specifications, and CRGs as risk adjusters, providing an alternative 
way of obtaining high predictive power comparable to other estimations of drug 
expenditures in the literature. These results have clear implications for the use of risk 
adjustment and CRGs in setting the premiums for pharmaceutical benefits. 
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Introduction 
 
The growth of pharmaceutical expenditures is a current major concern for health policy 
makers in Spain. There, drug expenditures have grown in the last decade to represent 
around 23% of total health expenditures in 2004 [1]. As a consequence, the policy 
agenda is focused on how these increasing expenditures should be financed and 
consider issues like copayment, how to selectively finance medicines, or introducing 
price competition in generic drugs [2]. This paper proposes risk adjustment as a tool for 
predicting drug expenditures and for setting the premiums for pharmaceutical benefits 
using individual data. We apply several specifications for the estimation beyond the 
usual linear specification and compare our predictability results with others from the 
literature. 
The analysis of pharmaceutical consumption should start with information about what is 
prescribed and for which pathology, what is consumed and how much it costs at 
individual level. In order to establish a relationship between pharmaceutical 
consumption and morbidity, we need two essential sources: individual information 
about pharmaceutical costs and morbidity. Up to now, these sources have been difficult 
to get and therefore, the debate has focused on averages and growth rates, providing 
little information to take decisions at policy and management level [3].  
Although several studies have used pharmacy data to predict total health care costs 
[4,5,6,7,8,9], only a few have addressed the issue of predictability of drug spending. A 
feasible explanation is that usually private insurers do not offer free standing drug 
benefits, and public programs offering those benefits have not developed private risk-
based contracts [10]. Using only demographic information and past cost, two studies in   4
the 1990s [11,12] showed the highly persistent behavior of drug expenditures and the 
low predictive power of using only demographic information (from  02 . 0
2 = R to 
04 . 0
2 = R ). Adding health status (morbidity) information through the diagnosis cost 
group/hierarchical condition category (DCG/HCC) risk-adjustment methodology 
[10,13], different prospective models obtain higher predicting power with an R
2 
between 0.10 and 0.24, while adding lag expenditures raised it to 0.55 [10]. Lastly, 
Pharmacy Categories (Rx-Groups) have also been used to predict pharmacy costs [13] 
obtaining an 
2 R  near 0.50, and therefore explaining almost half of the variation of the 
cost in the subsequent year.  
This paper fits in the literature predicting drug expenditures using a classification 
system for health status that allows to understand population morbidity [14,15]. We 
apply the Clinical Risk Groups (CRGs) classification system, which allows classifying 
individuals in mutually exclusive categories attending to their clinical conditions. It 
differs from the DCG/HCC methodology, that allows multiples categories for each 
individual. The CRG methodology uses information from the encounters between the 
health system and the patients, and allocates a severity level to each patient [16]. The 
uniqueness of the CRGs compared to other methods is that it supports clinical 
meaningfulness, the severity levels and its multiple applications. 
In this paper, we link pharmaceutical consumption (outpatient, specialist, and hospital) 
and the morbidity in a publicly funded healthcare system environment using CRGs as a 
risk adjustment system. In our estimations we use three different specifications. Then 
we test the predictive power of our different models and compare our results to others in 
the literature. Finally, as a policy implication and based on our findings, we advocate 
the use of risk adjustment in setting the premiums for pharmaceutical benefits.   5
  
Data 
We utilize individual demographic (age and sex) and morbidity data in year 2002 and 
pharmaceutical expenditures in 2002 and 2003 from 87,691 individuals belonging to the 
Serveis de Salut Integrats Baix Empordà (SSIBE), an integrated health care delivery 
organization in Catalonia, Spain. For inpatient services, population covered by the 
integrated delivery system can use the only hospital in the county – Palamós Hospital –, 
while for outpatient services there are five different primary care areas. In our analysis 
we use primary care, specialized care, and inpatient consumption of pharmaceuticals for 
all individuals belonging to four primary care areas:  Palamós, Torroella, la Bisbal and 
Palafrugell. In 2002 there were 52,916 individuals (60.35% of population) with non-
zero drug expenditures, consuming 1,206,008 prescriptions worth a total 15,124,842 
euros, including public funding (CatSalut), out-of-pocket payment (copayment), and 
hospital consumption. The fifth primary care area – Sant Feliu de Guíxols – is out of the 
analysis because of incomplete data.  
The database contains 1,241,127 procedures and diagnostic codes for year 2002. Every 
encounter between individuals and the organization is identified, registered, and coded 
using ICD-9-CM (The International Classification of Diseases, 9th Revision, Clinical 
Modification), allowing the allocation of pharmacy costs by individuals. The CRG 
grouping assigns one CRG category to each patient. We use the maximum level of 
aggregation allowed by the CRG classification system, collecting morbidity in 9 
different patient groups. Table 1 shows the demographic characteristics of the 
population and the composition of the 9 CRG categories. The CRG system assigns one 
level of severity to each patient within the CRG category, so that in our database   6
individuals are classified in 37 different risk groups (ACRG3), while the grouper 




This paper estimates different models in order to predict drug expenditures in the 
subsequent year. Our objective is to examine the predictive properties of different 
models which use different information and how well they explain future cost. The 
basic model is characterized by: 
) , , , , ( , 1 , , 1 , 1 , , t i t i t t i i t i t i itures DrugExpend us HealthStat sex age f itures DrugExpend ε − − − =  
Thus, drug expenditures in year t for individual i are explained by some independent 
variables or risk adjusters. Model 1 uses only demographic information (age and sex). 
Model 2 considers also information on drug expenditures incurred by the individual last 
year (t-1). Model 3 uses only prospective information on health status in previous year 
(t-1) provided by the CRG classification system. Model 4 is a prospective model using 
both demographic and health status information in previous year. Models 5 and 6 are 
concurrent models analogous to models 3 and 4. Thus, model 5 uses only health status 
information in year t in order to explain drug expenditures in year t, and model 6 uses 
also demographic information.   
The typical specification in the risk adjustment literature is a simple specification, in 
which individuals are assigned to, say, age-sex cells. This specification is nonparametric 
in the sense that the parameters of the expectation conditional on age and sex are of free 
variation. In this paper we also consider two other specifications: a “parametric” 
specification in which the sex and age of each individual enter as independent variables   7
in a nonlinear specification (sex, age, age
2, age
3, age
4); and a more flexible parametric 
specification which, for convenience, can be termed as “flexible-parametric”, in which 







4). Our dependent variable, drug expenditures, is a 
censored variable ( 0 ≥ itures DrugExpend ) with a large number of zeros (39.65%). 
Therefore, besides of using OLS, we also run a tobit estimation in our different model 
specifications.  
The main indicator we use in order to measure how well the different model predicts is 
the
2 R  that measures the proportion of the variation of future costs that the model 
predicts. Another indicator widely used is the Predictive Ratio (PR) [17,18,19], which 
is the ratio of predicted cost to actual cost within a group of individuals of interest. If 
the predictive ratio is very close to one, the model predicts well for that group of 
individuals. If  1 < PR , the model underpredicts for those individuals, and if  1 > PR , it 
overpredicts. We randomly divide the population in two subsets: the estimation sample 
and the validation sample. We obtain the predictive models from the estimation sample 
and calculate the PR for the validation sample for individuals of different demographic 
cells (age and sex) and for individuals belonging to different CRG categories. 
Lastly, we provide a third indicator, Validated-
2 R  (
2 ~
R ), obtained using the predicted 
model from the estimation sample in the validation sample, and calculating the ratio of 
the sum of squares explained by that predicted model to the ratio of total sum of squares 
in the validating sample. 
 
 
Results   8
 
Table 2 shows the
2 R and the Validated-
2 R  (
2 ~
R ) for the different predictive models 
analyzed under our different model specifications for both, OLS and tobit estimations. 
The proportion of explained variance increases with the quality of information used in 
the model. With respect to prospective models, model 1 (only demographic 
information) presents an 
2 R  close to 9%, while in the case of model 3, with only health 
status information through the CRG classification system, it is of 21%. When 
demographic and CRG information are combined (model 4), the proportion of 
explained variance is around 24%. In concurrent models, the same relationship is 
obtained with higher predictive power, improving the 
2 R  from around 30% using only 
CRG information (model 5) to 32% when demographic information is added (model 6). 
Although the normal use of risk adjustment is restricted to OLS linear nonparametric 
estimations, we have considered two more flexible alternative specifications, 
“parametric” and “flexible-parametric”, in order to evaluate whether the role of 
demographic characteristics and its interaction and clinical conditions could be better 
explored. However, we have found very similar
2 R  in the three specifications, meaning 
that with only demographic and CRG information, “nonparametric” models work as 
well as “parametric” or “flexible-parametric” models, being simpler to interpret and use. 
Estimations from “nonparametric” models are very precise; and given the low 
correlation between age and sex, we obtain consistent and robust estimators. We also 
tried another “flexible-parametric” specification using the interaction of age and clinical 
conditions (CRG) but results were not improved. The 
2 ~
R  obtained for the validating 
sample from predictions in the estimation sample are normally slightly lower but follow 
the same pattern than the
2 R  reported, validating the results. Tobit estimations obtained   9
in general a lower
2 R  than OLS models, although they predict better drug expenditures 
for non users.  
Table 3 shows the Predictive Ratio (PR) calculated for the different prospective models 
and for different groups of individuals, by clinical conditions and by age and sex. The 
demographic models overpredict drug expenditures for healthy individuals while 
underpredict those expenditures for the rest. Models using CRG information obtain PR 
very close to 1 for the different groups by clinical conditions, but model 4, using also 
demographic information also obtains very close to 1 PR for the different demographic 
groups, being specially good for predicting drug expenditure of healthy individuals 
( 99 . 0 = PR ) or for female older than 80 ( 99 . 0 = PR ). 
Thus, adding diagnostic information through the CRG classification system from only 
demographic information in our sample obtains similar results than adding that 
information through HCC/DCG in other samples as has been shown in the literature 
until a maximum 
2 R  of 0.24 [10,13] in prospective models and with a higher 
2 R  of  
0.66 in the case of concurrent models. Therefore, the CRG classification system has 
shown in this sample of individual data to be an alternative to other classification 
systems as the HCC/DCG in order to predict drug expenditures 
 
Conclusions 
The growth of pharmaceutical expenditure has created a need to improve its prediction 
in order to set appropriate budgets. In this paper we present the Clinical Risk Group 
classifications system (mutually exclusive categories providing individual clinical 
conditions and severity level) as an alternative to other morbidity classifications 
systems. Our results present CRGs as a risk adjuster with similar predicting power for   10
drug expenditures to other methods in prospective models and some higher proportion 
of variance explained in concurrent models. Provided the predictive power, the use of 
prospective risk adjustment is recommended in setting premiums for pharmaceutical 
benefits or in setting a budget constraint of public expenditures taking into account the 
characteristics or risks of the covered population. As a next step, once premiums and 
budgets are set adjusted to population characteristics and risks, risk adjustment is 
potentially profitable as a tool for controlling the drug expenditure and providing 
incentives for efficiency in the use of pharmaceutical benefits.  
   11
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Table 1: Demographic characteristics of the population. N= 87691 individuals. 
 




Age (mean)  41,48
0 to 14  13,50%
15 to 29  20,49%
30 to 44  24,72%
45 to 64  21,56%
65 to 79  13,07%
80 or older  6,66%
  
Aggregated Clinical Risk Group categories of patients   
Healthy  72,73%
History of Significant Acute Disease  6,49%
Single Minor Chronic Disease  5,61%
Minor Chronic Disease in Multiple Organ Systems  0,82%
Single Dominant or Moderate Chronic Disease  9,78%
Disease in Chronic Multiple Organ Systems  3,75%
Dominant Chronic Disease in Three or More Organ Systems 0,26%
Dominant and Metastatic Malignancies  0,40%
Catastrophic Conditions  0,15%
  
  
Total drug expenditures in 2002 € (mean)  162,24
(Std. Deviation)  544,4
Total drug expenditures in 2003 € (mean)  187,67




















   15
Table 2: : 
2 R  and 
2 ~
R obtained from the different predictive models 
 
  
2 R  
2 ~
R  
   N=43912  N=43799 
Prospective models    
  Model 1. Demographic information     
       Parametric OLS estimation  0,0939  0,0819 
       Parametric tobit estimation  0,0912  0,0804 
       Flexible-parametric OLS estimation  0,0940  0,0819 
       Flexible-parametric tobit estimation  0,0896  0,0791 
       Nonparametric OLS estimation  0,0884  0,0771 
  Model 2: Demographic and last year cost     
       Parametric OLS estimation  0,6659  0,7706 
       Parametric tobit estimation  0,7091  0,8327 
       Flexible-parametric OLS estimation  0,6659  0,7704 
       Flexible-parametric tobit estimation  0,6245  0,7293 
       Nonparametric OLS estimation  0,6660  0,7713 
  Model 3: Only health status information (CRGs)     
        Nonparametric OLS estimation  0,2131  0,1923 
 
Model 4: Demographic and health status information 
(CRGs)    
       Parametric OLS estimation  0,2397  0,2157 
       Parametric tobit estimation  0,1761  0,1564 
       Flexible-parametric OLS estimation  0,2402  0,2160 
       Flexible-parametric tobit estimation  0,1762  0,1564 
       Nonparametric OLS estimation  0,2380  0,2140 
Concurrent models    
  Model 5: Only health status information (CRGs)     
       Nonparametric OLS estimation  0,2956  0,2303 
 
Model 6: Demographic and health status information 
(CRGs)    
       Parametric OLS estimation  0,3283  0,2549 
       Parametric tobit estimation  0,2350  0,1810 
       Flexible-parametric OLS estimation  0,3291  0,2554 
       Flexible-parametric tobit estimation  0,2350  0,1809 
       Nonparametric OLS estimation  0,3267  0,2536   16
Table 3: Predictive Ratios for the different prospective models in the OLS estimation 
 
  






Model 4: Demographic and health 
status information (CRGs) 















total  43779 0,9902 0,9919 1,0000  1,0012 1,0014 1,0000  1,0000  1,0042 1,0049 1,0009 
Healthy  31838 1,9476 1,9509 1,9789  1,0816 1,0825 1,0863  1,0041  0,9959 0,9939 0,9906 
History of Significant Acute Disease  2845  0,8418 0,8453 0,8631  0,9225 0,9235 0,9260  0,7252  0,7174 0,7190 0,7230 
Single Minor Chronic Disease  2458  0,8559 0,8628 0,8502  1,0094 1,0112 1,0092  1,0292  1,0275 1,0278 1,0303 
Minor Chronic Disease in Multiple 
Organ Systems 
384  0,7298 0,7385 0,7113  0,9834 0,9859 0,9831  1,0842  1,0966 1,0946 1,0889 
Single Dominant or Moderate Chronic 
Disease 
4216  0,6238 0,6237 0,5987  0,9408 0,9408 0,9382  0,9715  0,9687 0,9680 0,9660 
Disease in Chronic Multiple Organ 
Systems 
1670  0,5011 0,5007 0,4815  0,9883 0,9881 0,9866  1,0719  1,0652 1,0645 1,0652 
Dominant Chronic Disease in Three 
or More Organ Systems 
124  0,3671 0,3654 0,3468  1,0893 1,0883 1,0866  0,8724  0,8720 0,8724 0,8716 
Dominant and Metastatic 
Malignancies 
178  0,5928 0,5904 0,5688  1,6095 1,6084 1,6055  1,2609  1,2732 1,2721 1,2719 
Catastrophic Conditions  66  0,0469 0,0464 0,0484  0,9386 0,9383 0,9394  1,2283  1,2326 1,2329 1,2334 
male 0-14  2789  2,1409 1,4123 0,9084  1,1120 0,9313 0,9535  4,4299  1,8389 1,1444 1,1302 
male 15-29  4511  1,2164 0,8611 0,9084  1,1108 1,0234 0,9955  2,5822  1,2296 0,8738 0,8737 
male 30-44  5216  0,9183 0,9565 1,2061  1,0524 1,0624 1,1136  1,5405  0,9644 0,9695 1,1005 
male 45-64  4626  1,1251 1,1934 1,0654  1,0453 1,0632 1,0400  0,9095  1,0761 1,1385 1,0756 
male 65-79  2926  0,9888 1,0011 1,0546  0,9825 0,9877 1,0028  0,6951  1,0065 1,0301 1,0556 
male +80  1788  1,0260 1,0120 0,9843  1,0062 1,0088 0,9900  0,6499  0,9842 0,9812 0,9633 
female 0-14  3087  0,8849 1,7384 0,9199  0,7965 1,0131 1,0008  3,7238  0,9634 1,4746 0,8931 
female 15-29  4549  0,4066 0,5968 0,6523  0,8137 0,8593 0,9192  1,5947  0,3798 0,6024 0,7179 
female 30-44  5655  0,6953 0,6509 0,9284  1,0652 1,0519 1,0367  1,6641  0,7886 0,7882 0,9189 
female 45-64  4829  1,2454 1,1708 0,9962  1,0838 1,0651 1,0450  1,1164  1,2080 1,1300 1,0246 
female 65-79  2736  0,8864 0,8727 0,9139  0,9654 0,9597 0,9842  0,6779  0,9292 0,9044 0,9355 
female +80  1067  0,9466 0,9639 0,9436  1,0103 1,0055 0,9551  0,7390  1,0172 1,0211 0,9972 
 